EE05150B1 - Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod - Google Patents

Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Info

Publication number
EE05150B1
EE05150B1 EEP200100430A EEP200100430A EE05150B1 EE 05150 B1 EE05150 B1 EE 05150B1 EE P200100430 A EEP200100430 A EE P200100430A EE P200100430 A EEP200100430 A EE P200100430A EE 05150 B1 EE05150 B1 EE 05150B1
Authority
EE
Estonia
Prior art keywords
methylsulfone
vin
fluorophenyl
pyrimidine
dioxane
Prior art date
Application number
EEP200100430A
Other languages
English (en)
Estonian (et)
Inventor
Philip Taylor Nigel
Koike Haruo
Kabaki Mikio
Joseph Diorazio Louis
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05150(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Priority to EEP200900043A priority Critical patent/EE05531B1/xx
Publication of EE200100430A publication Critical patent/EE200100430A/xx
Publication of EE05150B1 publication Critical patent/EE05150B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100430A 1999-02-17 2000-02-15 Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod EE05150B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903472.0A GB9903472D0 (en) 1999-02-17 1999-02-17 Chemical process
PCT/GB2000/000481 WO2000049014A1 (en) 1999-02-17 2000-02-15 Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Publications (2)

Publication Number Publication Date
EE200100430A EE200100430A (et) 2002-12-16
EE05150B1 true EE05150B1 (et) 2009-04-15

Family

ID=10847843

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
EEP200100430A EE05150B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Country Status (34)

Country Link
US (2) US6844437B1 (da)
EP (1) EP1155015B1 (da)
JP (3) JP2003518474A (da)
KR (1) KR100648160B1 (da)
CN (1) CN1145625C (da)
AR (1) AR022600A1 (da)
AT (1) ATE415398T1 (da)
AU (1) AU760145B2 (da)
BR (1) BRPI0008301B8 (da)
CA (1) CA2362594C (da)
CL (1) CL2003002336A1 (da)
CY (1) CY1108733T1 (da)
CZ (1) CZ299844B6 (da)
DE (1) DE60040905D1 (da)
DK (1) DK1155015T3 (da)
EE (2) EE05531B1 (da)
ES (1) ES2316349T3 (da)
GB (1) GB9903472D0 (da)
HK (1) HK1041265B (da)
HU (1) HU229835B1 (da)
IL (2) IL144793A0 (da)
IS (1) IS2711B (da)
MX (1) MXPA01008235A (da)
NO (1) NO320739B1 (da)
NZ (1) NZ513261A (da)
PL (1) PL218518B1 (da)
PT (1) PT1155015E (da)
RU (1) RU2243969C2 (da)
SI (1) SI1155015T1 (da)
SK (1) SK286988B6 (da)
TR (2) TR200401874T2 (da)
TW (1) TWI285202B (da)
WO (1) WO2000049014A1 (da)
ZA (1) ZA200106370B (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
EP1417180B1 (en) * 2001-07-13 2006-12-27 AstraZeneca UK Limited Preparation of aminopyrimidine compounds
SK1402004A3 (sk) * 2001-08-16 2005-01-03 Teva Pharmaceutical Industries Ltd. Spôsob prípravy vápenatých solí statinov
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2003288443B2 (en) 2002-12-16 2007-10-25 Astrazeneka Uk Limited Process for the preparation of pyrimidine compounds
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
US20090124803A1 (en) * 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
EP1869005A1 (en) * 2005-04-04 2007-12-26 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
JP5146965B2 (ja) * 2005-06-24 2013-02-20 レツク・フアーマシユーテイカルズ・デー・デー 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法
SI1915349T1 (sl) * 2005-06-24 2016-05-31 Lek Pharmaceuticals D.D. Postopek za pripravo čistega amorfnega rosuvastatin kalcija
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1912953B1 (en) 2005-07-28 2016-08-17 LEK Pharmaceuticals d.d. Process for the synthesis of rosuvastatin calcium
JP2008515931A (ja) 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
CN100352821C (zh) * 2005-08-22 2007-12-05 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙中间体的制备方法
CN100436428C (zh) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2079712A2 (en) 2006-10-31 2009-07-22 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008072078A1 (en) 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
US8212035B2 (en) 2007-02-08 2012-07-03 Aurobindo Pharma Ltd. Process for preparation of rosuvastatin calcium field of the invention
WO2008130678A2 (en) 2007-04-18 2008-10-30 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and process for the preparation of rosuvastatin
JP2010533188A (ja) 2007-07-12 2010-10-21 テバ ファーマシューティカル インダストリーズ リミティド ロバスタチン中間体及びその製法
CA2696381A1 (en) 2007-08-28 2009-03-05 Ratiopharm Gmbh Process for preparing pentanoic diacid derivatives
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
SI2309992T1 (en) 2008-06-27 2018-03-30 Krka, Tovarna Zdravil, D.D., Novo Mesto A pharmaceutical composition comprising a statin
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
EP2350025A1 (en) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited An improved process for preparing pyrimidine propenaldehyde
CN102186869A (zh) * 2008-10-20 2011-09-14 株式会社钟化 新嘧啶衍生物及HMG-CoA还原酶抑制剂中间体的制造方法
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
KR20100080432A (ko) * 2008-12-29 2010-07-08 한미약품 주식회사 스타틴 화합물의 신규 제조방법 및 이에 사용되는 벤조티아졸릴 술폰 화합물
EA019995B1 (ru) 2009-01-14 2014-07-30 Крка, Товарна Здравил, Д.Д., Ново Место Соль розувастатина, способ ее получения и способ получения фармацевтически приемлемой соли розувастатина
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
KR101157314B1 (ko) * 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
CN103313983B (zh) * 2011-01-18 2016-06-29 中化帝斯曼制药有限公司荷兰公司 在碱存在下制备他汀类化合物的方法
US8865900B2 (en) 2011-01-18 2014-10-21 Dsm Sinochem Pharmaceuticals Netherlands B.V. Methyltetrazole sulfides and sulfones
US9150562B2 (en) 2011-01-18 2015-10-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of diol sulfones
WO2012172564A1 (en) * 2011-05-25 2012-12-20 Dr. Reddy's Laboratories Limited Process for preparation of rosuvastatin calcium
WO2013083718A1 (en) 2011-12-09 2013-06-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of a statin precursor
HUE032936T2 (en) 2011-12-09 2017-11-28 Dsm Sinochem Pharm Nl Bv A method for producing thioprecursors of statins
KR20130087153A (ko) * 2012-01-27 2013-08-06 코오롱생명과학 주식회사 로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물
CN103232398B (zh) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 一种瑞舒伐他汀氨基酸盐及其制备方法和应用
KR101292743B1 (ko) * 2012-05-17 2013-08-02 (주) 에프엔지리서치 신규한 스타틴 중간체 및 이를 이용한 피타바스타틴, 로수바스타틴, 세리바스타틴 및 플루바스타틴의 제조 방법
CN103864697A (zh) * 2012-12-11 2014-06-18 润泽制药(苏州)有限公司 瑞舒伐中间体主链醇的制备方法
WO2014108795A2 (en) 2013-01-10 2014-07-17 Aurobindo Pharma Limited An improved process for the preparation of chiral diol sulfones and statins
CN103420919B (zh) * 2013-08-22 2015-07-08 南京欧信医药技术有限公司 一种嘧啶类衍生物的合成方法
WO2015037018A1 (en) * 2013-09-14 2015-03-19 Ind-Swift Laboratories Limited Process for the preparation of rosuvastatin via novel intermediates
PT3115367T (pt) 2014-03-07 2018-01-04 Asymchem Laboratories Fuxin Co Ltd Composto intermediário para preparar rosuvastatina cálcica e método para preparar rosuvastatina cálcica a partir deste
CN103936680B (zh) * 2014-04-18 2016-08-24 润泽制药(苏州)有限公司 瑞舒伐他汀钙已知杂质的制备方法
CN104788387A (zh) * 2015-04-17 2015-07-22 浙江海森药业有限公司 高纯度瑞舒伐他汀钙的制备方法
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法
CN106478518A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种庚烯酸环戊酯衍生物的制备方法
KR101953575B1 (ko) 2016-10-24 2019-05-24 한양대학교 에리카산학협력단 스타틴계 고지혈증 치료제 합성을 위한 새로운 중간체 합성 및 이를 이용한 로수바스타틴 합성 공정 개발
CN108997324A (zh) * 2018-08-21 2018-12-14 南京欧信医药技术有限公司 瑞舒伐他汀钙中间体的制备方法
CN109651259B (zh) * 2018-12-29 2020-05-19 浙江永太科技股份有限公司 一种瑞舒伐他汀钙关键中间体的纯化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline

Also Published As

Publication number Publication date
BR0008301B1 (pt) 2013-01-22
DE60040905D1 (de) 2009-01-08
HU229835B1 (en) 2014-09-29
US6844437B1 (en) 2005-01-18
WO2000049014A1 (en) 2000-08-24
HUP0200301A3 (en) 2004-03-29
CY1108733T1 (el) 2014-04-09
CN1340052A (zh) 2002-03-13
JP4130844B2 (ja) 2008-08-06
IL163375A (en) 2008-12-29
TR200102360T2 (tr) 2001-12-21
SK11832001A3 (sk) 2002-01-07
PT1155015E (pt) 2009-01-27
CZ299844B6 (cs) 2008-12-10
EE05531B1 (et) 2012-04-16
KR100648160B1 (ko) 2006-11-24
US20040049036A1 (en) 2004-03-11
SI1155015T1 (sl) 2009-04-30
MXPA01008235A (es) 2002-04-24
HK1041265A1 (en) 2002-07-05
NO20013994D0 (no) 2001-08-16
HK1041265B (zh) 2009-07-03
ATE415398T1 (de) 2008-12-15
JP2008255114A (ja) 2008-10-23
ZA200106370B (en) 2002-11-04
BRPI0008301B8 (pt) 2021-05-25
NO320739B1 (no) 2006-01-23
CL2003002336A1 (es) 2005-01-14
AU2557300A (en) 2000-09-04
CN1145625C (zh) 2004-04-14
CA2362594A1 (en) 2000-08-24
TR200401874T2 (tr) 2004-10-21
DK1155015T3 (da) 2009-03-02
IS2709B3 (is) 2011-01-15
NO20013994L (no) 2001-10-16
ES2316349T3 (es) 2009-04-16
EP1155015A1 (en) 2001-11-21
BR0008301A (pt) 2002-01-22
EP1155015B1 (en) 2008-11-26
NZ513261A (en) 2003-10-31
PL350185A1 (en) 2002-11-18
JP2003518474A (ja) 2003-06-10
IS6029A (is) 2001-07-31
IL144793A0 (en) 2002-06-30
HUP0200301A2 (en) 2002-08-28
JP2007291113A (ja) 2007-11-08
RU2243969C2 (ru) 2005-01-10
TWI285202B (en) 2007-08-11
AR022600A1 (es) 2002-09-04
KR20010102207A (ko) 2001-11-15
SK286988B6 (sk) 2009-08-06
GB9903472D0 (en) 1999-04-07
AU760145B2 (en) 2003-05-08
PL218518B1 (pl) 2014-12-31
IS2711B (is) 2011-01-15
CA2362594C (en) 2009-06-02
EE200900043A (et) 2010-02-15
CZ20012930A3 (cs) 2001-11-14
EE200100430A (et) 2002-12-16
US6784171B2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
EE05150B1 (et) Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
HUP0101122A3 (en) Process for the preparation of optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
WO2000047583A8 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones
AU7414300A (en) Method for the production of substituted pyrimidine derivatives
NO20006039D0 (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
PT1185274E (pt) Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4
WO2003002580A8 (en) 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
AU6878500A (en) Novel 2-(2-pyridyl)pyrimidine derivatives
DK1095035T3 (da) Fremgangsmåde til fremstilling af 4-(3-pyridinyl)-1H-imidazol og de anvendte mellemprodukter
ITMI991731A0 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piper idine
DK1202949T3 (da) Fremgangsmåde til fremstilling af acylerede 1,3-dicarbonylforbindelser
DK1413575T3 (da) Fremgangsmåde til fremstilling af derivater af (1,5-diaryl)pyrazol-3-ylpropansyre
AU3231500A (en) Process for the preparation of 6-(perfluoroalkyl) uracil compounds from urea compounds
FR2797443B1 (fr) Procede de prepartion de quinoleine-5,8-diones
NO20012028D0 (no) Fremgangsmåte for fremstilling av 4-((2',5'-diamino-6'- halogenpyrimidin-4'-yl)amino)-cyclopent-2-enyl-metanoler
DK1104415T3 (da) Fremgangsmåde til fremstilling af 1,3-oxathiolan-nukleosider
IL176734A (en) Method for the preparation of 1 - (6 - methylpyridine - 3 - yl) - 2 - [4 - (methylsulfonyl) phenyl] ethanone
AU2002351830A1 (en) Diastereoselective process for the preparation of the antiviral agent4-amino-1-(2r-hydroxymethyl-(1,3)oxathiolan-5s-yl)-1h-pyrimidin-2-one

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231